The worldwide market for Biosimilar Monoclonal Antibodies Market is expected to grow at a CAGR of roughly 35.7% over the next ten years, and will reach US$ 32,015.0 Mn in 2026, from US$ 1,516.9 Mn in 2016, according to a new Market.us (Prudour Research) study.
Type:Rituximab, Infliximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab
Application: Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Others
By Region: Asia Pacific is projected to register the highest CAGR of around 36.0% over the forecast period and is expected to be valued around US$ 8,900.0 Mn in 2026.
Americas dominated the global biosimilar monoclonal antibodies market in revenue terms and is estimated to account for largest market revenue contribution of US$ 618.4 million in 2017 as compared to that of markets in other regions.
Source: https://market.us/infographics/biosimilar-monoclonal-antibodies-market/
Score from the experts at Killer Visual Strategies
Visual Communication - 35%
Design - 35%
Content - 35%
Usability - 35%
35%
Final Grade
This infographic shares data on medical drugs, with revenue by drug class and region. The initial section is a bit visually confusing, because the breakdown of the body in the same colors of the drug classes implies that the body is data visualization, as well as the bar graphs next to it. Since not much numerical data is provided — only the CAGR for Adalimumab — it's difficult to verify what's correct and what the real growth percentages are. Similarly, the next section only shares data for the Americas. Without an intro or conclusion, alongside the lack of numerical data throughout, it's unclear what the takeaways should be for the viewer. We'd give this an F.
